Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCACNASDAQ:BVXVNASDAQ:PTENASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCACBrookline Capital Acquisition$2.95$0.86$9.50▼$27.74$19.90M-0.0339,682 shs29,998 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shsWINTWindtree Therapeutics$0.91+6.7%$1.38$0.81▼$737.44$3.32M0.82744,458 shs219,914 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCACBrookline Capital Acquisition0.00%0.00%0.00%-87.01%-87.01%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%WINTWindtree Therapeutics+6.99%-10.84%-31.62%-88.63%-99.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCACBrookline Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APTEPolarityTEN/AN/AN/AN/AN/AN/AN/AN/AWINTWindtree Therapeutics2.0767 of 5 stars3.04.00.00.01.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCACBrookline Capital Acquisition 0.00N/AN/AN/ABVXVBiondVax Pharmaceuticals 0.00N/AN/AN/APTEPolarityTE 0.00N/AN/AN/AWINTWindtree Therapeutics 2.00Hold$350.0038,386.91% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCACBrookline Capital AcquisitionN/AN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/APTEPolarityTE$810K0.00N/AN/A$2.30 per share0.00WINTWindtree TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCACBrookline Capital Acquisition-$480KN/A0.00∞N/AN/A-416.32%-4.75%N/ABVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/APTEPolarityTE-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/AWINTWindtree Therapeutics-$20.29M-$823.47N/AN/AN/AN/A-362.76%-79.65%5/21/2025 (Estimated)Latest BVXV, WINT, PTE, and BCAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/AWINTWindtree Therapeutics-$39.00N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCACBrookline Capital AcquisitionN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/APTEPolarityTEN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCACBrookline Capital AcquisitionN/A0.070.07BVXVBiondVax PharmaceuticalsN/A4.124.12PTEPolarityTEN/A4.114.11WINTWindtree TherapeuticsN/A0.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCACBrookline Capital Acquisition51.83%BVXVBiondVax Pharmaceuticals11.83%PTEPolarityTE11.75%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipBCACBrookline Capital Acquisition19.20%BVXVBiondVax Pharmaceuticals6.03%PTEPolarityTE5.40%WINTWindtree Therapeutics0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCACBrookline Capital Acquisition66.75 million5.45 millionNot OptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionablePTEPolarityTE427.38 million6.98 millionOptionableWINTWindtree Therapeutics303.65 million11.01 millionNot OptionableBVXV, WINT, PTE, and BCAC HeadlinesRecent News About These CompaniesWindtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025May 12 at 8:00 AM | globenewswire.comWindtree Therapeutics Unveils U.S. Exclusivity Strategy for IstaroximeMay 10 at 7:14 PM | msn.comWindtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic ShockMay 8, 2025 | nasdaq.comWindtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for USMay 6, 2025 | globenewswire.comBiotech Company Jumps Into Houston Multifamily In Quest For Revenue Amid Stock SlideMay 5, 2025 | bisnow.comWhy biotech firm Windtree Therapeutics is buying a 436-unit apartment complexMay 5, 2025 | bizjournals.comWindtree Therapeutics Announces Plans to Acquire Multifamily Residential PropertyMay 5, 2025 | msn.comWindtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline DevelopmentMay 1, 2025 | finance.yahoo.comWindtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business UpdatesApril 15, 2025 | markets.businessinsider.comEvofem announces license and supply agreement with Windtree TherapeuticsMarch 27, 2025 | markets.businessinsider.comEvofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree TherapeuticsMarch 26, 2025 | prnewswire.comWindtree Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementMarch 24, 2025 | quiverquant.comWindtree Therapeutics Regains Compliance with Nasdaq Listing RulesMarch 24, 2025 | globenewswire.comWindtree Therapeutics (NASDAQ:WINT) Stock, Insider Trading ActivityMarch 21, 2025 | benzinga.comWindtree to become sourcing partner for Evofem BiosciencesMarch 21, 2025 | markets.businessinsider.comWindtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI®March 21, 2025 | msn.comAnother Day, Another Biotech Ripping Before The BellMarch 20, 2025 | msn.comWindtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved ProductMarch 20, 2025 | globenewswire.comWINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating CoverageMarch 4, 2025 | msn.comWindtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart FailureMarch 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumTime to Buy Alibaba and PDD After Tariff Exemptions?By Gabriel Osorio-Mazilli | April 17, 2025View Time to Buy Alibaba and PDD After Tariff Exemptions?T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip By Jea Yu | April 29, 2025View T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Lemonade: Leveraging AI to Underwrite a Path to Profitability By Jea Yu | April 16, 2025View Lemonade: Leveraging AI to Underwrite a Path to Profitability BVXV, WINT, PTE, and BCAC Company DescriptionsBrookline Capital Acquisition NASDAQ:BCACBrookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.BiondVax Pharmaceuticals NASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.PolarityTE NASDAQ:PTEPolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.Windtree Therapeutics NASDAQ:WINT$0.91 +0.06 (+6.71%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$0.95 +0.04 (+4.24%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
